#1 Clinical Trials Search in Europe

Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

3 1 1 1

What is this study about?

This clinical trial is focused on studying a type of breast cancer known as inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer. This type of cancer cannot be removed by surgery and has spread to other parts of the body. The study is comparing a new treatment called Datopotamab deruxtecan (also known by its code name DS-1062a) with other chemotherapy options chosen by doctors. These chemotherapy options include Eribulin mesylate, Gemcitabine, Capecitabine, and Vinorelbine. The purpose of the study is to see if Datopotamab deruxtecan is more effective than the other chemotherapy treatments in improving the condition of patients with this type of breast cancer.

Participants in the study will receive either Datopotamab deruxtecan or one of the chemotherapy treatments chosen by their doctor. The study will monitor the participants over time to see how their cancer responds to the treatment. This includes looking at how long the cancer stays under control and the overall survival of the participants. The study will also assess the side effects of the treatments and how they affect the participants’ quality of life.

The study is designed to provide important information about the effectiveness and safety of Datopotamab deruxtecan compared to standard chemotherapy options. This information could help doctors make better treatment decisions for patients with inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer in the future. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

1 joining the study

Upon joining the study, eligibility is confirmed based on specific criteria, including age, type of breast cancer, and previous treatments.

A negative pregnancy test is required for women of childbearing potential, and appropriate contraceptive measures must be in place.

2 randomization

Participants are randomly assigned to receive either Datopotamab deruxtecan or a chemotherapy option chosen by the investigator.

The chemotherapy options include eribulin mesylate, gemcitabine, capecitabine, and vinorelbine.

3 treatment administration

If assigned to Datopotamab deruxtecan, it is administered through an intravenous infusion.

If assigned to chemotherapy, the specific drug determines the method of administration: eribulin mesylate, gemcitabine, and vinorelbine are given via intravenous infusion, while capecitabine is taken orally.

4 treatment duration

The treatment continues until disease progression, unacceptable side effects, or withdrawal from the study.

Regular assessments are conducted to monitor the response to treatment and any side effects.

5 follow-up

After treatment ends, follow-up visits are scheduled to monitor health status and any long-term effects.

The study aims to assess progression-free survival and overall survival among participants.

Who Can Join the Study?

  • Participants must be at least 18 years old at the time of screening.
  • Participants must have inoperable or metastatic hormone receptor-positive (HR+), HER2-negative breast cancer. This means the cancer cannot be removed by surgery or has spread to other parts of the body, and it tests positive for certain hormone receptors but negative for a protein called HER2.
  • Participants must have tried and not be suitable for endocrine therapy (hormone therapy) and have been treated with 1 to 2 lines of chemotherapy for their inoperable or metastatic cancer. They must have shown progression on their most recent chemotherapy treatment.
  • Participants must be eligible for one of the chemotherapy options listed as ICC, which include eribulin, capecitabine, vinorelbine, or gemcitabine, as assessed by the investigator.
  • Participants must have an ECOG Performance Status of 0 or 1, which means they are fully active or have some symptoms but do not require bed rest.
  • Participants must have at least one measurable lesion that has not been previously treated with radiation, according to specific criteria (RECIST 1.1). Participants with only bone metastases are not allowed.
  • Participants with a history of treated spinal cord compression or inactive brain metastases can join if they do not need treatment with steroids or anticonvulsants and have recovered from radiation therapy effects. At least 2 weeks must have passed since the end of radiation therapy.
  • Participants must have adequate organ and bone marrow function, which includes specific levels of hemoglobin, neutrophils, platelets, bilirubin, liver enzymes (ALT and AST), and kidney function (creatinine clearance).
  • Participants must have a Left Ventricular Ejection Fraction (LVEF) of at least 50%, which is a measure of heart function, assessed by an echocardiogram or MUGA scan within 28 days of the first dose.
  • Participants must have had an adequate washout period from previous treatments before starting the study, which means a certain amount of time must have passed since their last major surgery, radiation therapy, or anticancer therapy.
  • Participants must have a formalin-fixed paraffin-embedded (FFPE) tumor sample available at the time of screening.
  • Participants must have a minimum life expectancy of 12 weeks at screening.
  • Participants must use contraception consistent with local regulations, and women must not use estrogens. Women of childbearing potential must have a negative pregnancy test and use effective birth control. Men must use condoms with spermicide and not donate sperm during the study.
  • Participants must be capable of giving signed informed consent, meaning they understand and agree to participate in the study.

Who Cannot Join the Study?

  • Patients who have not been diagnosed with inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer. This means the cancer cannot be removed by surgery or has spread to other parts of the body, and it is a specific type of breast cancer that does not have a protein called HER2.
  • Patients who have not been treated with one or two prior lines of systemic chemotherapy. This refers to cancer treatment that uses drugs to reach cancer cells throughout the body.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Azienda Ospedaliero Universitaria Careggi Florence Italy
Oncopole Claudius Regaud Toulouse France
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie Koszalin Poland
Hospital Clinico San Carlos Madrid Spain
Universitaetsklinikum Heidelberg AöR Heidelberg Germany
Universitaet Leipzig Leipzig Germany
Katholieke Universiteit te Leuven Leuven Belgium

Other Sites

Site Name City Country Status
Istituto Oncologico Veneto Padua Italy
Central Hospital Of Northern Pest Military Hospital Budapest Hungary
Orszagos Onkologiai Intezet Budapest Hungary
Istituto Europeo Di Oncologia S.r.l. Milan Italy
Centre hospitalier universitaire de Liege Liege Belgium
Hospital Universitari Dexeus Grupo Quironsalud Barcelona Spain
Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet Szolnok Hungary
Studienzentrum Onkologie Ravensburg GmbH Ravensburg Germany
Hospital Universitario Basurto Bilbao Spain
Instytut Msf Sp. z o.o. Lodz Poland
Bialostockie Centrum Onkologii Im. Marii Sklodowskiej-Curie W Bialymstoku Bialystok Poland
Tolna Vármegyei Balassa János Kórház Szekszard Hungary
Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o. Tomaszow Mazowiecki Poland
Virgen del Rocío University Hospital Sevilla Spain
Ospedale San Raffaele S.r.l. Milan Italy
Istituto Di Candiolo Fondazione Del Piemonte Per Loncologia IRCCS Candiolo Italy
Hospital Clinic De Barcelona Barcelona Spain
Saarland University Hospital Homburg Germany
Azienda USL Toscana Centro Prato Italy
Rotkreuzklinikum Muenchen gGmbH Munich Germany
Fondazione I.R.C.C.S. Istituto Neurologico Besta Milan Italy
Hospital Universitario Virgen De La Victoria Malaga Spain
Iduhjmix Cdczzv Dekcmuvuqynbexiim L'hospitalet De Llobregat Spain
Smkktiee Poornymat Svp z ooer Gdynia Poland
Pdyksmyfhga Lssugwqe &dpfayaxsamxyeyuthkh Rkwmw Kxuqgrwjgqb Konin Poland
Idgfseno Rxizankxd Pvt Lg Sskjcw Dpu Tnunqm Ddgj Axctjpj Ixzh Seplse Meldola Italy
Ngryzjqi Iqjdyhjb Owvrqgfvh Ijs Mpokz Shofljtucvymbipcrrhhirqwvkai Iqkjwvob Bkydvhvi Cracow Poland
Akppjjw Uwuuo Sdhkbauql Lxkcuo Dk Btlggyw Bologna Italy
Unvgczpdgbmasz Cjhmjsz Kromaiixj Gdansk Poland
Hxzhnqkr Uerlzscesunua dm A Coleeo A Coruna Galicia Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
21.01.2022
France France
Not recruiting
21.01.2022
Germany Germany
Not recruiting
21.01.2022
Hungary Hungary
Not recruiting
21.01.2022
Italy Italy
Not recruiting
21.01.2022
Poland Poland
Not recruiting
21.01.2022
Spain Spain
Not recruiting
21.01.2022

Trial locations

Investigated drugs:

Dato-DXd is an investigational medication being studied for its potential to treat breast cancer that is hormone receptor-positive and HER2-negative. This type of breast cancer does not respond to hormonal therapies or HER2-targeted treatments. Dato-DXd is being tested to see if it can help patients whose cancer has spread or cannot be surgically removed, and who have already received one or two previous chemotherapy treatments. The goal is to determine if Dato-DXd can improve progression-free survival and overall survival compared to other chemotherapy options chosen by the study investigators.

Investigated diseases:

Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer – This type of breast cancer is characterized by the presence of hormone receptors but lacks the HER2 protein, which influences the growth of cancer cells. It is termed “inoperable” when surgery is not a viable option due to the extent or location of the cancer. “Metastatic” indicates that the cancer has spread beyond the breast to other parts of the body. The progression of this disease involves the cancer cells continuing to grow and spread, often requiring systemic treatments like chemotherapy. Patients with this condition have typically undergone one or two prior lines of systemic chemotherapy. The disease’s behavior can vary, with some cases progressing more slowly than others.

Trial ID:
2023-509631-37-00
Protocol code:
D9268C00001
NCT ID:
NCT05104866
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A Phase I/II Study of GVV858 Alone or in Drug Combination for Patients with Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy Spain

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Spain